Antifungal susceptibilities of Candida glabrata species complex, Candida krusei, Candida parapsilosis species complex and Candida tropicalis causing invasive candidiasis in China: 3 year national surveillance

Journal of Antimicrobial Chemotherapy

Volumn 70, Issue 3, 2015, Pages 802-810

  Xiao, Meng ^a   Fan, Xin ^a,b   Chen, Sharon C A ^c   Wang, He ^a,b   Sun, Zi Yong ^d   Liao, Kang ^e   Chen, Shu Lan ^f   Yan, Yan ^g   Kang, Mei ^h   Hu, Zhi Dong ⁱ   Chu, Yun Zhuo ^j   Hu, Tie Shi ^k   Ni, Yu Xing ^l   Zou, Gui Ling ^m   Kong, Fanrong ^c   Xu, Ying Chun ^a  

^a PEKING UNION MEDICAL COLLEGE HOSPITAL   (China)

^b GRADUATE SCHOOL OF PEKING UNION MEDICAL COLLEGE   (China)

^c UNIVERSITY OF SYDNEY   (Australia)

^d HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^e THE FIRST AFFILIATED HOSPITAL OF SUN YAT SEN UNIVERSITY   (China)

^f THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

^g PEKING UNIVERSITY FIRST HOSPITAL   (China)

^h SICHUAN UNIVERSITY   (China)

ⁱ TIANJIN MEDICAL UNIVERSITY   (China)

^j CHINA MEDICAL UNIVERSITY   (China)

^k the People's Hospital of Liaoning Province   (China)

^l SHANGHAI JIAO TONG UNIVERSITY   (China)

^m HARBIN MEDICAL UNIVERSITY   (China)

more..

Author keywords

Antifungal susceptibility; C. glabrata species complex; C. krusei; C. parapsilosis species complex; C. tropicalis; china hospital invasive fungal surveillance net (chif net); Non albicans candida species species complexes

Indexed keywords

AMPHOTERICIN B; ANIDULAFUNGIN; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; MICAFUNGIN; POSACONAZOLE; PYRROLE DERIVATIVE; VORICONAZOLE;

ANTIFUNGAL SUSCEPTIBILITY; ARTICLE; ASCITES FLUID; BLOOD CULTURE; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CHINA; DISK DIFFUSION; DNA SEQUENCE; FUNGUS ISOLATION; IN VITRO STUDY; INVASIVE CANDIDIASIS; LUNG LAVAGE; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MINIMUM INHIBITORY CONCENTRATION; MULTICENTER STUDY; NONHUMAN; PHENOTYPE; PICHIA KUDRIAVZEVII; PROSPECTIVE STUDY; SPECIES DISTRIBUTION; SPECIES IDENTIFICATION; ANTIFUNGAL RESISTANCE; CANDIDA; CANDIDIASIS, INVASIVE; CLASSIFICATION; CLINICAL TRIAL; DRUG EFFECTS; EPIDEMIOLOGICAL MONITORING; HOSPITAL; HUMAN; ISOLATION AND PURIFICATION; MASS SPECTROMETRY; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PREVALENCE;

ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS, INVASIVE; CHINA; DRUG RESISTANCE, FUNGAL; EPIDEMIOLOGICAL MONITORING; HOSPITALS; HUMANS; MICROBIAL SENSITIVITY TESTS; PREVALENCE; PROSPECTIVE STUDIES; SEQUENCE ANALYSIS, DNA; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84928191342     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku460     Document Type: Article

References (46)

1. Arnold HM, Micek ST, Shorr AF et al. Hospital resource utilization and costs of inappropriate treatment of candidemia. Pharmacotherapy 2010; 30: 361-8.
2. Falagas ME, Apostolou KE, Pappas VD. Attributable mortality of candidemia: a systematic review of matched cohort and case-control studies. Eur J Clin Microbiol Infect Dis 2006; 25: 419-25.
3. Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clin Infect Dis 1998; 27: 781-8.
4. Zaoutis TE, Argon J, Chu J et al. The epidemiology and attributable outcomes of candidemia in adults and children hospitalized in the United States: a propensity analysis. Clin Infect Dis 2005; 41: 1232-9.
5. Gonzalez GM, Trevino-Rangel Rde J, Palma-Nicolas JP et al. Species distribution and antifungal susceptibility of bloodstream fungal isolates in paediatric patients in Mexico: a nationwide surveillance study. J Antimicrob Chemother 2013; 68: 2847-51.
6. Miceli MH, Diaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis 2011; 11: 142-51.
7. Pfaller MA, Diekema DJ, Gibbs DL et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study, 1997 to 2007: a 10.5-year analysis of susceptibilities of Candida species to fluconazole and voriconazole as determined by CLSI standardized disk diffusion. J ClinMicrobiol 2010; 48: 1366-77.
8. Nucci M, Queiroz-Telles F, Tobon AM et al. Epidemiology of opportunistic fungal infections in Latin America. Clin Infect Dis 2010; 51: 561-70.
9. Wang H, Xiao M, Chen SC et al. In vitro susceptibilities of yeast species to fluconazole and voriconazole as determined by the 2010 National China Hospital Invasive Fungal Surveillance Net (CHIF-NET) study. J Clin Microbiol 2012; 50: 3952-9.
10. Guo F, Yang Y, Kang Yet al. Invasive candidiasis in intensive care units in China: a multicentre prospective observational study. J Antimicrob Chemother 2013; 68: 1660-8.
11. Montagna MT, Caggiano G, Lovero G et al. Epidemiology of invasive fungal infections in the intensive care unit: results of a multicenter Italian survey (AURORA Project). Infection 2013; 41: 645-53.
12. Puig-Asensio M, Peman J, Zaragoza R et al. Impact of therapeutic strategies on the prognosis of candidemia in the ICU. Crit Care Med 2014; 42: 1423-32.
13. Pfaller MA, Diekema DJ. Epidemiology of invasive mycoses in North America. Crit Rev Microbiol 2010; 36: 1-53.
14. Chen S, Slavin M, Nguyen Q et al. Active surveillance for candidemia, Australia. Emerg Infect Dis 2006; 12: 1508-16.
15. Adhikary R, Joshi S. Species distribution and anti-fungal susceptibility of candidaemia at a multi super-specialty center in Southern India. Indian J Med Microbiol 2011; 29: 309-11.
16. Chander J, Singla N, Sidhu SK et al. Epidemiology of Candida blood stream infections: experience of a tertiary care centre in North India. J Infect Dev Ctries 2013; 7: 670-5.
17. Chen SC, Marriott D, Playford EG et al. Candidaemia with uncommon Candida species: predisposing factors, outcome, antifungal susceptibility, and implications for management. Clin Microbiol Infect 2009; 15: 662-9.
18. Pfaller MA, Diekema DJ, Colombo AL et al. Candida rugosa, an emerging fungal pathogen with resistance to azoles: geographic and temporal trends from the ARTEMIS DISK antifungal surveillance program. J Clin Microbiol 2006; 44: 3578-82.
19. Xiao M, Wang H, Lu J et al. Three clustered cases of candidemia caused by Candida quercitrusa and mycological characteristics of this novel species. J Clin Microbiol 2014; 52: 3044-8.
20. Liu W, Tan J, Sun J et al. Invasive candidiasis in intensive care units in China: in vitro antifungal susceptibility in the China-SCAN study. J Antimicrob Chemother 2014; 69: 162-7.
21. Clinical and Laboratory Standards Institute. Method for Antifungal Disk Diffusion Susceptibility Testing of Yeasts-Second Edition: Approved Guideline M44-A2. CLSI, Wayne, PA, USA, 2009.
22. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts-Third Edition: Approved Standard M27-A3. CLSI, Wayne, PA, USA, 2008.
23. Clinical and Laboratory Standards Institute. Reference Method for Broth Dilution Antifungal Susceptibility Testing of Yeasts: Fourth Informational Supplement M27-S4. CLSI, Wayne, PA, USA, 2012.
24. Huang YT, Liu CY, Liao CH et al. Antifungal susceptibilities of Candida isolates causing bloodstream infections at a medical center in Taiwan, 2009-2010. Antimicrob Agents Chemother 2014; 58: 3814-9.
25. Zhang L, Xiao M, Wang H et al. Yeast identification algorithm based on use of the Vitek MS system selectively supplemented with ribosomal DNA sequencing: proposal of a reference assay for invasive fungal surveillance programs in China. J Clin Microbiol 2014; 52: 572-7.
26. Orasch C, Marchetti O, Garbino J et al. Candida species distribution and antifungal susceptibility testing according to EUCAST and new vs. old CLSI clinical breakpoints: a six-year prospective candidemia survey from the fungal infection network of Switzerland (FUNGINOS). Clin Microbiol Infect 2013; 20: 698-705.
27. Pfaller MA, Boyken L, Hollis RJ et al. Comparison of results of fluconazole and voriconazole disk diffusion testing for Candida spp. with results from a central reference laboratory in the ARTEMIS DISK Global Antifungal Surveillance Program. Diagn Microbiol Infect Dis 2009; 65: 27-34.
28. Liao Y, Chen M, Hartmann T et al. Epidemiology of opportunistic invasive fungal infections in China: review of literature. Chin Med J (Engl) 2013; 126: 361-8.
29. Pfaller MA, Messer SA, Woosley LN et al. Echinocandin and triazole antifungal susceptibility profiles for clinical opportunistic yeast and mold isolates collected from 2010 to 2011: application of new CLSI clinical breakpoints and epidemiological cutoff values for characterization of geographic and temporal trends of antifungal resistance. J Clin Microbiol 2013; 51: 2571-81.
30. Lockhart SR, Messer SA, Pfaller MA et al. Geographic distribution and antifungal susceptibility of the newly described species Candida orthopsilosis and Candida metapsilosis in comparison to the closely related species Candida parapsilosis. J Clin Microbiol 2008; 46: 2659-64.
31. Canton E, Peman J, Quindos G et al. Prospective multicenter study of the epidemiology, molecular identification, and antifungal susceptibility of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis isolated from patients with candidemia. Antimicrob Agents Chemother 2011; 55: 5590-6.
32. Bonfietti LX, Martins Mdos A, Szeszs MWet al. Prevalence, distribution and antifungal susceptibility profiles of Candida parapsilosis, Candida orthopsilosis and Candida metapsilosis bloodstream isolates. J Med Microbiol 2012; 61: 1003-8.
33. Bertini A, De Bernardis F, Hensgens LA et al. Comparison of Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis adhesive properties and pathogenicity. Int J Med Microbiol 2013; 303: 98-103.
34. Pfaller MA, Castanheira M, Lockhart SR et al. Frequency of decreased susceptibility and resistance to echinocandins among fluconazoleresistant bloodstream isolates of Candida glabrata. J Clin Microbiol 2012; 50: 1199-203.
35. Pham CD, Iqbal N, Bolden CB et al. Role of FKS mutations in Candida glabrata: MIC values, echinocandin resistance, and multidrug resistance. Antimicrob Agents Chemother 2014; 58: 4690-6.
36. Borman AM, Petch R, Linton CJ et al. Candida nivariensis, an emerging pathogenic fungus with multidrug resistance to antifungal agents. J Clin Microbiol 2008; 46: 933-8.
37. Chou HH, Lo HJ, Chen KW et al. Multilocus sequence typing of Candida tropicalis shows clonal cluster enriched in isolates with resistance or trailing growth of fluconazole. Diagn Microbiol Infect Dis 2007; 58: 427-33.
38. Li SY, Yang YL, Lin YH et al. Two closely related fluconazole-resistant Candida tropicalis clones circulating in Taiwan from 1999 to 2006. Microb Drug Resist 2009; 15: 205-10.
39. Pappas PG, Kauffman CA, Andes D et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis 2009; 48: 503-35.
40. Alexander BD, Byrne TC, Smith KL et al. Comparative evaluation of Etest and sensititre yeastone panels against the Clinical and Laboratory Standards Institute M27-A2 reference broth microdilution method for testing Candida susceptibility to seven antifungal agents. J Clin Microbiol 2007; 45: 698-706.
41. Espinel-Ingroff A, Pfaller M, Messer SA et al. Multicenter comparison of the Sensititre YeastOne colorimetric antifungal panel with the NCCLS M27-A2 reference method for testing new antifungal agents against clinical isolates of Candida spp. J Clin Microbiol 2004; 42: 718-21.
42. Pfaller MA, Andes D, Arendrup MC et al. Clinical breakpoints for voriconazole and Candida spp. revisited: review of microbiologic, molecular, pharmacodynamic, and clinical data as they pertain to the development of species-specific interpretive criteria. Diagn Microbiol Infect Dis 2011; 70: 330-43.
43. Pfaller MA, Andes D, Diekema DJ et al. Wild-type MIC distributions, epidemiological cutoff values and species-specific clinical breakpoints for fluconazole and Candida: time for harmonization of CLSI and EUCAST broth microdilution methods. Drug Resist Updat 2010; 13: 180-95.
44. Canton E, Peman J, Hervas D et al. Comparison of three statistical methods for establishing tentative wild-type population and epidemiological cutoff values for echinocandins, amphotericin B, flucytosine, and six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol 2012; 50: 3921-6.
45. Canton E, Peman J, Iniguez C et al. Epidemiological cutoff values for fluconazole, itraconazole, posaconazole, and voriconazole for six Candida species as determined by the colorimetric Sensititre YeastOne method. J Clin Microbiol 2013; 51: 2691-5.
46. Arendrup MC. Candida and candidaemia. Susceptibility and epidemiology. Dan Med J 2013; 60: B4698.